163 related articles for article (PubMed ID: 15525492)
1. [Clinical use of calcimimetics in the treatment of hyperparathyroidisms].
Urena P
Med Sci (Paris); 2004 Nov; 20(11):973-8. PubMed ID: 15525492
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Calcimimetics, mechanisms of action and therapeutic applications].
Ureña P; Legoupil N; de Vernejoul MC
Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
[TBL] [Abstract][Full Text] [Related]
4. Calcimimetic agents: review and perspectives.
Ureña P; Frazão JM
Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
[TBL] [Abstract][Full Text] [Related]
5. Use of calcimimetics in uremic patients with secondary hyperparathyroidism: review.
Ureña P
Artif Organs; 2003 Sep; 27(9):759-64. PubMed ID: 12940896
[TBL] [Abstract][Full Text] [Related]
6. Role of calcium-sensing receptor in mineral ion metabolism and inherited disorders of calcium-sensing.
Chattopadhyay N; Brown EM
Mol Genet Metab; 2006 Nov; 89(3):189-202. PubMed ID: 16919492
[TBL] [Abstract][Full Text] [Related]
7. Calcimimetics and calcilytics--fooling the calcium receptor.
Steddon SJ; Cunningham J
Lancet; 2005 Jun 25-Jul 1; 365(9478):2237-9. PubMed ID: 15978932
[TBL] [Abstract][Full Text] [Related]
8. [New insights into the pharmacology of the extracellular calcium sensing receptor].
Ruat M; Petrel C
Med Sci (Paris); 2004 Nov; 20(11):980-5. PubMed ID: 15525493
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic use of calcimimetics.
Hebert SC
Annu Rev Med; 2006; 57():349-64. PubMed ID: 16409154
[TBL] [Abstract][Full Text] [Related]
10. [Calcimimetics].
Messa P; Como G; Brezzi B
G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
[TBL] [Abstract][Full Text] [Related]
11. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
[TBL] [Abstract][Full Text] [Related]
12. Clinical lessons from the calcium-sensing receptor.
Brown EM
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):122-33. PubMed ID: 17237839
[TBL] [Abstract][Full Text] [Related]
13. [Parathyroid gland, calcium receptor and calcimimetics].
Ureña P
Nephrologie; 2002; 23(4):151-64. PubMed ID: 12125321
[TBL] [Abstract][Full Text] [Related]
14. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans.
Cañadillas S; Canalejo A; Santamaría R; Rodríguez ME; Estepa JC; Martín-Malo A; Bravo J; Ramos B; Aguilera-Tejero E; Rodríguez M; Almadén Y
J Am Soc Nephrol; 2005 Jul; 16(7):2190-7. PubMed ID: 15888568
[TBL] [Abstract][Full Text] [Related]
15. Novel calcium sensing receptor ligands: a patent survey.
Kiefer L; Leiris S; Dodd RH
Expert Opin Ther Pat; 2011 May; 21(5):681-98. PubMed ID: 21406038
[TBL] [Abstract][Full Text] [Related]
16. [Basic and clinical aspects of calcimimetics. Discovery and development of calcimimetics].
Nagano N
Clin Calcium; 2008 Jan; 18(1):37-44. PubMed ID: 18175870
[TBL] [Abstract][Full Text] [Related]
17. Persistence of Ca2+-sensing receptor expression in functionally active, long-term human parathyroid cell cultures.
Roussanne MC; Gogusev J; Hory B; Duchambon P; Souberbielle JC; Nabarra B; Pierrat D; Sarfati E; Drüeke T; Bourdeau A
J Bone Miner Res; 1998 Mar; 13(3):354-62. PubMed ID: 9525335
[TBL] [Abstract][Full Text] [Related]
18. Calcium-sensing receptor and calcimimetic agents.
Coburn JW; Elangovan L; Goodman WG; Frazaõ JM
Kidney Int Suppl; 1999 Dec; 73():S52-8. PubMed ID: 10633465
[TBL] [Abstract][Full Text] [Related]
19. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
Nagano N
Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
[TBL] [Abstract][Full Text] [Related]
20. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism.
Cunningham J
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V9-14. PubMed ID: 15284354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
